IMF Focuses on Education for Blood Cancer Awareness Month
For this Blood Cancer Awareness Month, observed each September, the International Myeloma Foundation (IMF) is focusing on educating people about multiple myeloma, the…
News
Pepaxti Approved to Treat Resistant Multiple Myeloma in Europe
The European Commission has approved Pepaxti (melphalan flufenamide, also called melflufen), a medicine by Oncopeptides to be used in combination with dexamethasone, making it…
Abecma May Be Effective Early Therapy for Hard-to-treat Myeloma
Note: This story was updated Sept. 26, 2022, to correct the fact that Abecma is approved for patients in Europe and Japan who have undergone…
Telo, Mayo Clinic Working on Tests to ID Patients at Risk of Relapse
Telo Genomics has teamed up with the Mayo Clinic to develop tests to help clinicians identify multiple myeloma (MM) patients at high risk of…
Continuous Low-Dose Lenalidomide Safe in Healthy People in Trial
STAR-LLD, an investigational continuous delivery of low doses of lenalidomide into the blood — being developed as a new treatment option for multiple…
Teclistamab Plus Darzalex Found to Ease Cancer Burden in Phase 1 Trial
A combination of the investigational therapy teclistamab and the approved medication Darzalex (daratumumab) reduced the cancer burden for most people with relapsed or refractory…
Nexpovio Triple Combo Approved as Myeloma Treatment in Europe
The European Commission has granted full approval to a triple combination therapy of Nexpovio (selinexor) — sold in the U.S. as Xpovio —  to treat…
Tecvayli Recommended for Conditional Approval in Europe
A branch of the European Medicines Agency (EMA) has recommended that Janssen’s investigational therapy Tecvayli (teclistamab) be granted conditional marketing authorization for adults with…
Pepaxti Combo Favored to Treat Advanced Multiple Myeloma in EU
Oncopeptides received a positive opinion from an arm of the European Medicines Agency (EMA) that is expected to take the company one step closer…
List of Rare Diseases Tops 10,000 – and Is Growing – New Analysis Finds
Note: This story was updated July 13, 2022, to correct the name of Rare-X’s CEO Charlene Son Rigby. Nonprofits, scientists, governmental organizations, and…
Recent Posts
- Low muscle mass linked to worse outcomes with chemoradiotherapy
- Dordaviprone under FDA priority review for aggressive glioma type
- FDA decision on linvoseltamab in treating RRMM expected in July
- CUSP06 put on FDA fast track for platinum-resistant ovarian cancer
- Tuspetinib as part of triple-combo therapy showing potential in AML